MYND’s Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC, Jan. 12, 2022 /CNW/ – MYND Life...

VANCOUVER, BC, Dec. 15, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) is pleased to announce it...

R&D project on psilocybin’s benefits in treating diseases of the brain VANCOUVER, BC, Nov. 30, 2021 /CNW/ – MYND Life Sciences...

R&D project on psilocybin’s benefits in treating diseases of the brain VANCOUVER, BC, Nov. 30, 2021 /CNW/ – MYND Life Sciences Inc. ...

MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis...

The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease...

Focused on generating data through proprietary biomarkers and diagnostic testing of inflammation VANCOUVER, BC, Nov. 9, 2021 /CNW/ – MYND...

VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ – MYND Life Sciences Inc. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) announces the...

Acquisition will strengthen MYND’s psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the...

Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression VANCOUVER, BC, Oct. 13, 2021 /CNW/ – MYND...

VANCOUVER, BC, Oct. 11, 2021 /PRNewswire/ — MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF), based in Vancouver BC, focused on novel...

MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other...

VANCOUVER, BC, Sept. 29, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“), has granted an aggregate of 234,192 restricted...

VANCOUVER, BC, Sept. 9, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“) is pleased to announce,...

VANCOUVER, BC, Aug. 26, 2021 /PRNewswire/ – MYND Life Sciences Inc.  (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“), is pleased to...

VANCOUVER, BC, Aug. 11, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND”) is a drug research and development...

VANCOUVER, BC, July 7, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND”) is a drug research and development company...

“Diagnosing, preventing and treating diseases of the central nervous system is at the core of our focused corporate strategy.”...

VANCOUVER, BC, June 23, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on...

VANCOUVER, BC, June 17, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on...